Michael Moradi

Biography

Mr. Michael Moradi, also known as Mike, is a Co-Founder, Chairman and Chief Executive Officer of Sensulin, LLC. Mr. Moradi is a successful entrepreneur and founded or been a principal in several Nanotech and biopharma startups. He was a co-founder and CEO of an ocular pharmaceutical company and specialty Contract Research Organization (CRO). He co-founded Southwest Nanotechnologies (“SWeNT”) and Nanopolaris (now Unidym). Mr. Moradi served as Vice President of Marketing at SouthWest Nanotechnologies, Inc. Mr. Moradi is a serial entrepreneur, whose last startup involvement was nanomaterial company NanoSource, which became the first acquisition of a nanotech firm by a Fortune 500 Co. He has been involved with several technology startups, including a biomaterials firm and a software company. Mr. Moradi served as a Technology Auditor of Phillips Petroleum, developing chemical and IT audit plans. He also served as a Research Technician of Phillips Petroleum, he helped develop microbial methods for removal of sulfides from hydrocarbons. He served as a Commercialization Consultant for the National Science Foundation. As a Technology Transfer Associate for the University of Oklahoma, he served on several licensing deals and spinoffs. Mr. Moradi holds a B.S in Biochemistry from the University of Oklahoma, where he is an Adjunct Instructor with the College of Engineering and Graduate College of Business. 

Research Interest

The company’s drug delivery platform is based upon a series of liposomes that are linked by a stimulus-responsive molecule, which can be used to encapsulate various drugs that are triggered by a variety of stimuli. It focuses on developing glucose-responsive insulin that may mimic a healthy human pancreas primarily for type I and type II diabetes.